MSLI Share Price

Open 0.83 Change Price %
High 0.83 1 Day 0.00 0.00
Low 0.81 1 Week -0.05 -5.68
Close 0.83 1 Month 0.07 9.21
Volume 2942 1 Year -0.32 -27.83
52 Week High 1.90
52 Week Low 0.00
MSLI Important Levels
Resistance 2 0.85
Resistance 1 0.84
Pivot 0.82
Support 1 0.82
Support 2 0.81
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
APRI 2.86 89.40%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
APRI 2.86 89.40%
AMCF 0.06 50.00%
LOCM 0.09 50.00%
SKBI 0.12 50.00%
UNXL 1.69 34.13%
LIFE 3.25 32.65%
CHCI 2.42 29.41%
GLBS 6.17 27.22%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
THTI 0.15 -40.00%
More..

Merus Labs International Inc. (NASDAQ: MSLI)

MSLI Technical Analysis 4
As on 18th Jan 2017 MSLI Share Price closed @ 0.83 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.17 & Sell for SHORT-TERM with Stoploss of 0.89 we also expect STOCK to react on Following IMPORTANT LEVELS.
MSLI Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
Merus Labs International Inc. ( NASDAQ USA Symbol : MSLI )
Sector : N/AIndustry:N/AFull Time Employees:N/ABusiness Summary Merus Labs International Inc., a specialty pharmaceutical company, is engaged in the acquisition and licensing of branded prescription medicines in the United States, Canada, and Europe. It offer And Other Stocks in Same Sector
MSLI
0.83 0.00 (0.00 %)
LT : Strong Sell
ST : Sell
MSLI Other Details
Segment EQ
Market Capital 45448548.00
Sector N/AIndustry:N/AFull Time Employees:N/ABusiness Summary Merus Labs International Inc., a specialty pharmaceutical company, is engaged in the acquisition and licensing of branded prescription medicines in the United States, Canada, and Europe. It offer
Industry N/AFull Time Employees:N/ABusiness Summary Merus Labs International Inc., a specialty pharmaceu
Offical website http://www.meruslabs.com
MSLI Address
MSLI
100 Wellington Street West
Suite 2110
Toronto, ON M5K 1H1
Canada
Phone: 416-593-3725
Fax: 416-593-4434
MSLI Latest News
Stocks Hitting 52-Week Lows   Benzinga   - 15th Dec 16
US shares lower at close of trade; Dow Jones Industrial Average down 0.60%   Investing.com UK   - 15th Dec 16
18 Biggest Mid-Day Losers For Wednesday   Benzinga   - 14th Dec 16
Royal Bank Of Canada Cuts Merus Labs International Inc (MSL) Price Target to C ...   BBNS   - 23rd Nov 16
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.32%   Investing.com   - 16th Aug 16
Merus Labs (MSLI) Tanks on Weak Q3 Financial Results   Economic Calendar   - 16th Aug 16
Slow Growth Ahead; Updates on Merus Labs International, Enghouse Systems ...   GuruFocus.com (registration)   - 05th Oct 15
Merus Labs International: A Pharma Stock With Growth Potential   GuruFocus.com (registration)   - 30th Mar 15
Vansen Pharma Inc. appoints new President and CEO   Canada NewsWire (press release)   - 03rd Mar 14
Merus Labs acquires Emselex rights from Novartis for Canada and Europe   Proactive Investors USA & Canada   - 11th Jul 12
Interactive Technical Analysis Chart Merus Labs International Inc. ( MSLI NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Merus Labs International Inc.
MSLI Business Profile
Merus Labs International Inc. (Merus), formerly Envoy Capital Group Inc., is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. It has products in the area of urology/women's health, anti-infective, and wound care. Its products include Factive, Emselex/Enable, Vancocin and Collacare and Collexa. On January 6, 2012, the Company acquired 51% of Orbis Pharma Inc. On March 7, 2012, the Company completed the acquisition of the North American product rights for FACTIVE (Gemifloxacin Mesylate) tablets from Cornerstone Therapeutics Inc. In August 2013, the Company announced that the divestiture of the North American product rights for FACTIVE (Gemifloxacin Mesylate) tablets to Okana Ventures Inc.